Cite

HARVARD Citation

    Verstovsek, S. et al. (2017). A phase 2 study of simtuzumab in patients with primary, post‐polycythaemia vera or post‐essential thrombocythaemia myelofibrosis. British journal of haematology. pp. 939-949. [Online]. 
  
Back to record